research T-Cell Reconstitution after Thymus Xenotransplantation Induces Hair Depigmentation and Loss
T-cell reconstitution after thymus transplantation can cause hair whitening and loss.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Immunopathogenesis of Primary Cicatricial Alopecia
Hair loss in Lichen Planopilaris is caused by immune system issues damaging hair follicles and stem cells.
research SARS‐CoV‐2 & androgenic alopecia: exploring links!
Possible link between COVID-19 and hair loss; more research needed.
research 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
Prostate cancer is common, but risk can be reduced by avoiding smoking, unhealthy diet, inactivity, certain medications, and risky jobs.
research Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research Species Differences in Prostatic Steroid 5α-Reductases of Rat, Dog, and Human
Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
research Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.
research Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
research 5α‐Reductase Isozymes and Androgen Actions in the Prostate
5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.
research Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen and Sexual Function in Healthy Young Men
Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.
research Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
research The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications
The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
research Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells
Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model
Low androgen levels might delay prostate cancer but could lead to more aggressive, therapy-resistant cancers.
research Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial
Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
research Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia
Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
research Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
Cinnamomi cortex may help treat prostate enlargement by reducing related proteins.
research Male pattern baldness and the risk of prostate cancer
Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research Patients with a large prostate show a higher prevalence of androgenetic alopecia
Large prostate links to more hair loss, but age of onset doesn't affect it.
research Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
research Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer
SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.
research Characteristics of flutamide action on prostatic and testicular functions in the rat
Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
research Male pattern baldness and prostate cancer risk in a population-based case–control study
Men who start losing hair at age 30 may have a lower risk of prostate cancer.
research Risks and side effects in the medical management of benign prostatic hyperplasia
Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.